Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey, by three brothers (Robert, James, and Edward Johnson). Inspired by the groundbreaking antiseptic theories of Joseph Lister, the company's foundational product was the first mass-produced, ready-to-use sterile surgical dressing. This immediately established J&J as an indispensable, trusted partner to the medical profession. Throughout the 20th century, J&J expanded into consumer products (inventing the Band-Aid in 1920) and acquired significant pharmaceutical companies (like Janssen Pharmaceutica in 1961), establishing a sprawling, diversified healthcare conglomerate.
The Tylenol Crisis (The Gold Standard of Crisis Management)
The defining, well-known moment in J&J's corporate history occurred in 1982. Seven people in Chicago died after consuming Tylenol capsules that had been maliciously laced with cyanide by an unknown individual. Unlike modern corporations that often deny responsibility to protect their stock price, J&J CEO James Burke executed an immediate, aggressive, extensive nationwide recall of 31 million bottles of Tylenol, costing the company hundreds of millions of dollars. The company then pioneered tamper-evident packaging. This decisive, ethical response saved the brand. The public trusted J&J more than ever, establishing a halo of "trust" that defined the company for decades.
The Talc Litigation and the "Texas Two-Step"
In the 21st century, that considerable halo of trust was severely damaged. J&J faced a major legal crisis regarding its well-known Baby Powder. Tens of thousands of aggressive lawsuits alleged that the talc used in the powder was contaminated with asbestos and caused significant rates of ovarian cancer. J&J denied the claims, but the juries awarded multi-billion-dollar verdicts. To contain this prominent financial liability, J&J attempted a controversial, aggressive legal maneuver known as the "Texas Two-Step." They attempted to push the specific subsidiary holding the talc liabilities into bankruptcy to force a settlement, a strategy that faced prominent legal and political blowback.
The Kenvue Spin-Off (Amputating the Consumer)
The prominent talc litigation, combined with the fact that selling baby shampoo generated lower profit margins than selling complex cancer drugs, led J&J to separate the business. In 2023, J&J officially spun off its vast, historic Consumer Health division (Tylenol, Band-Aid, Listerine) into a fully independent, publicly traded company named Kenvue. This significant, multi-billion-dollar maneuver was designed to isolate the high-margin, high-growth pharmaceutical and medical device divisions from the volatile, slow-growth legal liabilities of the legacy consumer brands.
The Dual Engine (Innovative Medicine and MedTech)
Today, the "new" Johnson & Johnson is a focused, lucrative dual-engine leader. The pharmaceutical division (Innovative Medicine) generates prominent cash flow from blockbuster drugs like Stelara (for immunology) and Darzalex (for multiple myeloma). Crucially, unlike pure-play pharmaceutical companies that constantly face bankruptcy when patents expire, J&J relies on its MedTech division. By manufacturing complex physical hardware (like artificial knees, surgical staplers, and advanced cardiovascular catheters), J&J possesses stable, predictable revenue streams, giving it more diversified revenue than most pure-play drugmakers.
2026: The $100 Billion Year and the Talc Deal
In 2026 J&J raised its sales guidance to about $101.1 billion, which would be its first year above $100 billion. In July 2026 it proposed an estimated $5.5 billion resolution of remaining ovarian talc claims, and it is preparing to separate its DePuy Synthes orthopaedics business by mid-2027.
